Skip to main
ORIC

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

Oric Pharmaceuticals (ORIC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ORIC Pharmaceuticals Inc. is positioned favorably within the clinical-stage biopharmaceutical sector, leveraging its expertise in hormone-dependent cancers, precision oncology, and tumor dependencies to develop innovative therapies like ORIC-944, ORIC-114, and ORIC-533. Recent clinical data highlight the strong efficacy and safety profile of its lead candidate, enozertinib, which has shown encouraging overall response rates and significant intracranial efficacy, along with a promising market opportunity valued at $3.0 to $3.5 billion annually for key patient cohorts in the U.S. Furthermore, the company's robust financial position ensures the capability to support pivotal clinical developments as it advances towards potential Phase 3 trials for multiple programs, underscoring a compelling investment proposition in the upcoming years.

Bears say

The financial outlook for ORIC Pharmaceuticals is considerably negative due to a projected full-year net loss of $1.28 per share for 2026, which reflects an increase from the prior estimate of $1.52 per share. Multiple risks threaten the company's ability to advance its key pipeline candidates, ORIC-114 and ORIC-944, including potential clinical and regulatory failures, delays in pivotal trial initiation, and inadequate market uptake leading to lower revenue projections. Furthermore, the ongoing risk of long-term dilution exacerbates concerns regarding the company's financial stability and long-term viability within the competitive biopharmaceutical industry.

Oric Pharmaceuticals (ORIC) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oric Pharmaceuticals (ORIC) Forecast

Analysts have given Oric Pharmaceuticals (ORIC) a Buy based on their latest research and market trends.

According to 10 analysts, Oric Pharmaceuticals (ORIC) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oric Pharmaceuticals (ORIC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.